⚡️ On European Urology - A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non–muscle-invasive Bladder Cancer #BladderCancer sciencedirect.com/science/articl…

🔪Liver transplant strategies in HCC ESMO - Eur. Oncology #ESMOGI25

✅Evolving sytemic treatment in HCC ESMO - Eur. Oncology #ESMOGI25

📊Treatment paterns in intermediate stage HCC ESMO - Eur. Oncology #ESMOGI25 ⏰OS of EMERALD-1 and LEAP-012❓

✅The treatment of advanced BTC expands rapidly in the last 5 years ESMO - Eur. Oncology #ESMOGI25 Arndt Vogel

🎯Targeting HER2 in BTC ESMO - Eur. Oncology #ESMOGI25 #cancer #oncology #MedX

Proposed therapeutic algorithm for mantle cell lymphoma including both clinically available and experimental drugs, expected in the near future mdpi.com/2072-6694/17/1… #lymsm

🚨 New Meta-Analysis in Metastatic non–Clear Cell RCC (nccRCC) Key pooled outcomes (23 studies): 🎯 ORR: 26.6% 🛡️ DCR: 57.8% ⏳ Median PFS: 6.6 months 📈 Median OS: 21.1 months Takeaway: ICI-based therapies, especially when combined with targeted agents, show superior efficacy

CUP is 2–5% of cancers but causes the 4th most cancer deaths. ⚠️ While tissue of origin can guide treatment, most patients see no clear benefit. ~33% have actionable mutations, targeted therapy won’t help all, but for some, it could change everything. rdcu.be/euSyo

Immune Checkpoint Inhibitor‐Based Therapy as the First‐Line Treatment for Advanced NSCLC. Efficacy, challenges & future perspectives, including bispecific antibody targeting PD-1 & VEGF. onlinelibrary.wiley.com/doi/10.1111/17… OncoAlert

The paper of the day: a landmark publication that is bound to serve as a reference for years to come! ⁦NatureRevClinOncol⁩ ⁦Thanos Dimopoulos⁩ ⁦COMy⁩ ⁦IACH⁩ ⁦Meral Beksac⁩ ⁦

What is resectable , borderline resectable and unresectable Gall bladder cancer . Nice slide by Dr Gonzalo ESMO - Eur. Oncology #ESMOGI2025

Is surgery for the primary tumor in stage IV breast cancer beneficial? Only one trial from turkey was positive for prolonging OS. Here’s the summary of the clinical trials! OncoAlert

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer (INAVO120) nejm.org/doi/full/10.10…

🧬 New narrative review on 1L treatment for advanced NSCLC: onlinelibrary.wiley.com/doi/10.1111/17… ✅ IO ± chemo/dual IO improves outcomes ❌ But 5y OS still ~25–30% 📉 Plateau demands innovation: biomarkers, new combos, better selection Time to break the checkpoint gridlock. The horizon

🌟🎓✔️🖋MUST READ Key Updates in Testicular Cancer: Optimizing Survivorship and Survival 👨‍⚕️ Authors: Dr. Lawrence Einhorn DrBagrodia Ragnhild Hellesnes Lucia Nappi Sia Daneshmand, M.D. University of British Columbia  Testicular Cancer Society IU School of Medicine Indiana University Department of Urology  IU Simon Comprehensive Cancer Center OncoAlert 🔹 Testicular cancer: high

What is beyond IO and TKI in HCC ? Bispecific and Anti TIGIT. Nice slides to show current data for both. ESMO - Eur. Oncology #esmogi2025

Treatment Algorithm: This is the algorithm we have used during our discussion w/ Deepa Rangachari, MD, FASCO for Stage I-III non-small cell #LungCancer #OncTwitter #MedTwitter #lcsm

📘Early-onset colorectal cancer ASCO Educational Book 👉ascopubs.org/doi/10.1200/ED… #cancer #oncology #MedX OncoAlert Dr Joseph McCollom DO

🧬 Testicular cancer is highly curable, even in advanced stages. Management is tailored by histology & risk. Multidisciplinary care is key: from fertility preservation to survivorship, follow-up, and quality of life. Advances in molecular diagnostics and targeted therapies